$NOVO B (-1,61%) and the battle for the 200-day line!

The Novo Nordisk share is currently stuck at the 200-day line after its strong rally from its low of 266.90 Danish kroner at the end of November. Recently, some analysts have also been rather cautious, which means that momentum is currently lacking. Meanwhile, investors should keep an eye on an important date.

Several analyst firms remain cautiously positioned on Novo Nordisk ahead of the fourth quarter figures, which are to be presented on February 4. UBS is sticking to its neutral assessment and sees the fair value of the share at 390 Danish kroner. The group's outlook for 2026 is expected to be rather defensive. The analysts believe that the oral version of the weight loss drug Wegovy will remain decisive, particularly with regard to its earning power.

Barclays also remains cautious and continues to rate the share at "Equal Weight". The target price is 360 crowns. Initial market signals following the start of sales of the tablet form of Wegovy at the beginning of January are highlighted as encouraging.

Jefferies is much more skeptical. The analyst firm confirms its sell recommendation with a target price of 270 crowns. In the short term, weekly sales data from Wegovy in particular will influence the share price. However, despite high demand at the beginning of the year, the analysts do not expect any noticeable positive effects on business development - neither in 2025 nor in 2026.

I feel very comfortable with my short. As long as we don't close above 400DKK, everything is in the green.

I have disposed of some shares in my portfolio and some new ones have made it into the portfolio

Sold:

$ASML (+2,96%) (+77.44 %) went well for me, I will possibly get back in if there is a strong setback

$PUM (+2,92%) (+5.76) I don't see much potential at the moment

$NOVO B (-1,61%) (2.53 %) I am waiting for a setback and will get back in lower

new additions to the portfolio today:

$ONDS (-3,09%)

$NOW (+0,35%)

$GIS (-0,55%)

added to the portfolio last week:

$ASPI (+0,81%)

$9880 (+4,75%)

The entry price doesn't quite fit...

I am taking this trade for two reasons

1. as a consolation in case the whole situation between Denmark/Europe versus the USA escalates.

2. and as a trade that the figures that will be presented soon will miss forecasts, at least in terms of profit...

Only accounts for 1.2% of my portfolio, so really only a small position of around €130...

LG small investor 👋

$NOVO B (-1,61%)

Oh well, there has to be a bit of excitement and fun. Therefore, as announced on the WE, short on $NOVO B (-1,61%)

What I did:

Sold: 25 shares $PLTR (-0,79%) at €153,40

Bought: 75 shares $NOVO B (-1,61%) at €50.50

Reason:

Why $PLTR (-0,79%) reduced?

• P/E ratio 2025: 307x - absurdly overvalued even for growth
• P/E ratio 2026: 218x - Still casino territory
• Had already sold 50% at +200% (unfortunately too early 🤦)
• I'll keep the remaining 25 shares for now.
• Risk management: Secure profits at such valuations

Why $NOVO B (-1,61%) in?

• Healthcare exposure is missing completely in my portfolio
• GLP-1 mega-trend: Oral Wegovy performing better than expected in the US
• Timing: Stock -61% from all-time high, fundamental story intact
• Valuation: P/E ratio 17x vs. PLTR's 307x - much more rational
• Long term: 25 year horizon, ageing population = healthcare growth

Risks I see:

• Eli Lilly competition
• Trump's tariff threat on Denmark (short-term political uncertainty)
• Patent cliffs long term
• Individual stock risk instead of healthcare ETF

My thoughts:

PLTR was a 10-bagger for me, but at P/E 307x it's getting too hot for me. Better to shift some profits into fundamentally more favorable quality stocks. Novo at -64% of top + oral pill launch = interesting risk/reward with a long horizon.

What do you think - justifiable decision or mistake?

Looking forward to your opinions! 🚀

• Should I have just let PLTR continue to run?
• Is Novo too risky as a single stock (better a healthcare ETF)?
• Is the timing with Novo ok or still too early?

Now that Trump is threatening punitive tariffs to get Greenland and he won't, I have decided to sell 115 of 175 shares in $NOVO B (-1,61%) at a loss of just under 1k.

In return, I bought the second tranche $RACE (+1,86%) for this. I want to buy in a total of 4 tranches.